M Dougados, J Braun, S Szanto, *et al*. Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebocontrolled study (SPINE). [*Ann Rheum Dis* 2011;**70**:799--804](http://ard.bmj.com/content/70/5/799.full) doi:10.1136/ard.2010.139261. The data published for ASDAS-CRP status at W12 in [Table 2](#T1){ref-type="table"} is incorrect. The data provided was the % of patients with changes during the study and not the % of patients at the end of the study. The correct table appears below:

###### 

Responder criteria after 12 weeks of therapy by treatment group

                                                  Treatment group                
  ----------------------------------------------- ----------------- ------------ ----------
  ASAS20                                          14 (33%)          25 (67%)     0.003
  ASAS40                                          10 (23%)          17 (44%)     0.053
  ASAS5/6                                         2 (5%)            8 (21%)      0.044
  ASAS partial remission                          2 (5%)            7 (18%)      0.073
  BASDAI 50                                       10 (23%)          18 (46%)     0.031
  ASDAS-CRP changes (W12-baseline)                                               
   ASDAS ≥1.1 (minimally important improvement)   7 (17.1)          25 (64.1)    \<0.0001
   ASDAS ≥2.0 (major improvement)                 1 (2.4)           15 (38.5)    \<0.0001
  ASDAS-CRP status at W12                                                        
   ASDAS \<1.3                                    2 (4.7%)          5 (12.8%)    0.249
   ASDAS \<2.1                                    5 (11.6%)         16 (41.0%)   0.005

ASAS = Ankylosing Spondylitis Activity Score; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, ASDAS = Ankylosing Spondylitis Disease Activity Score
